Kevin M. Koch

Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas

Howard A. Burris, Herbert I. Hurwitz, Elizabeth Claire Dees et al. · Journal of Clinical Oncology · 2005 · 625 citations · Full text

Medicine, Oncology, Pharmacology +17

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Tammie C. Yeh, Vivienne Marsh, Bryan A. Bernat et al. · Clinical Cancer Research · 2007 · 583 citations · Full text

Medicine, Oncology, Pharmacology +14

Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies

Neil L. Spector, Wenle Xia, Howard A. Burris et al. · Journal of Clinical Oncology · 2005 · 365 citations · Full text

Medicine, Oncology, Pharmacology +17

Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis.

R. Griffiths, E. R. Pettipher, Kevin M. Koch et al. · Proceedings of the National Academy of Sciences · 1995 · 317 citations

Medicine, Immunology, Pharmacology +17

A multispectral three‐dimensional acquisition technique for imaging near metal implants

Kevin M. Koch, John E. Lorbiecki, R. Scott Hinks et al. · Magnetic Resonance in Medicine · 2009 · 271 citations

Medicine, Orthopedic Surgery, Radiology +17